collection
MENU ▼
Read by QxMD icon Read
search

cardiotoxicity

shared collection
90 papers 0 to 25 followers
By Elvis Amao Internal Medicine , Cardiology and infectious diseases
https://www.readbyqxmd.com/read/28562342/association-between-obesity-and-trastuzumab-related-cardiac-toxicity-in-elderly-patients-with-breast-cancer
#1
Hai-Yan Wang, Bei-Bei Yin, Dan-Yan Jia, Ying-Long Hou
PURPOSE: Trastuzumab can improve the prognosis for patients with breast cancer, but its related cardiac toxicity is concerning. This study aimed to identify the risk factors associated with trastuzumab-related cardiac toxicity in elderly patients with HER2-positive breast cancer. PATIENTS AND METHODS: A total of 133 elderly (≥ 65 years) patients who were diagnosed with breast cancer between June 1, 2007, and January 31, 2016, and received trastuzumab treatment were retrospectively reviewed...
May 11, 2017: Oncotarget
https://www.readbyqxmd.com/read/28552383/transient-congenital-dilated-cardiomyopathy-after-maternal-r-chop-chemotherapy-during-pregnancy
#2
Stephanie Padberg, Inge Mick, Cornelia Frenzel, Richard Greil, Johannes Hilberath, Christof Schaefer
Pregnancy-associated diffuse large B-cell lymphoma (DLBCL) is a rare event. Experience regarding fetal effects of maternal treatment during pregnancy is limited. Cardiotoxicity is a known adverse effect of some antineoplastic agents especially of doxorubicin. We report a case of pregnancy-associated DLBCL, which was treated between gestational week 26 and 33 with three cycles of R-CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone combined with rituximab). At gestational age 34 2/7 she delivered a male infant who was admitted to neonatal care due to cardiomyopathy...
May 25, 2017: Reproductive Toxicology
https://www.readbyqxmd.com/read/28542097/genome-wide-association-and-pathway-analysis-of-left-ventricular-function-after-anthracycline-exposure-in-adults
#3
Quinn S Wells, Olivia J Veatch, Joshua P Fessel, Aron Y Joon, Rebecca T Levinson, Jonathan D Mosley, Elizabeth P Held, Chase S Lindsay, Christian M Shaffer, Peter E Weeke, Andrew M Glazer, Kevin R Bersell, Sara L Van Driest, Jason H Karnes, Marcia A Blair, Lore W Lagrone, Yan R Su, Erica A Bowton, Ziding Feng, Bonnie Ky, Daniel J Lenihan, Michael J Fisch, Joshua C Denny, Dan M Roden
BACKGROUND: Anthracyclines are important chemotherapeutic agents, but their use is limited by cardiotoxicity. Candidate gene and genome-wide studies have identified putative risk loci for overt cardiotoxicity and heart failure, but there has been no comprehensive assessment of genomic variation influencing the intermediate phenotype of anthracycline-related changes in left ventricular (LV) function. The purpose of this study was to identify genetic factors influencing changes in LV function after anthracycline chemotherapy...
July 2017: Pharmacogenetics and Genomics
https://www.readbyqxmd.com/read/28550591/cardiovascular-risk-in-survivors-of-cancer
#4
REVIEW
Henry Chen Zheng, Laura Onderko, Sanjeev A Francis
PURPOSE OF REVIEW: Survivors of childhood and adult cancers face increased risk of cardiovascular disease. We review the current evidence base and guidelines for this rapidly growing population. RECENT FINDINGS: Research continues to show that cardiovascular disease is an important cause of morbidity and mortality in cancer survivors. Cardiotoxicity related to chemotherapy and radiotherapy accounts for part of this increased risk. There is emerging evidence that cancer and cardiovascular disease share a similar biology and risk factors...
July 2017: Current Cardiology Reports
https://www.readbyqxmd.com/read/28453909/cardiotoxicity-and-cardiomyopathy-in-children-and-young-adult-survivors-of-hematopoietic-stem-cell-transplant
#5
REVIEW
Seth J Rotz, Thomas D Ryan, Joel Hlavaty, Stephen A George, Javier El-Bietar, Christopher E Dandoy
Cardiomyopathy is common in long-term survivors of pediatric hematopoietic stem cell transplant (HSCT). Events occurring before and after HSCT when combined with specific insults during HSCT likely contribute to long-term risk. Strategies for detecting subclinical cardiomyopathy prior to patients developing overt heart failure are under investigation. Changes in HSCT preparative regimens and cardioprotective medications administered during chemotherapy may alter the risk for cardiomyopathy. Interventions in long-term survivors such as lifestyle modification and cardioactive medications are of increasing importance...
April 28, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/28469492/diagnostic-strategies-for-early-recognition-of-cancer-therapeutics-related-cardiac-dysfunction
#6
REVIEW
Carlos R Manrique, Michael Park, Nidhish Tiwari, Juan Carlos Plana, Mario J Garcia
Cardiovascular toxicity in the form of cardiac dysfunction continues to be an obstacle for patients with cancer. Survival and quality of life of cancer survivors are frequently affected by increased incidence of cardiovascular disease. The involvement of the cardiovascular system by primary or secondary malignancies, as well as its dysfunction secondary to the administration of antineoplastics, has led to the development of a new discipline called Cardio-Oncology, an exciting cardiology subspecialty with more questions than answers and as a result an enormous opportunity for research in the field...
2017: Clinical Medicine Insights. Cardiology
https://www.readbyqxmd.com/read/28505345/cardio-oncology-a-multidisciplinary-approach-for-detection-prevention-and-management-of-cardiac-dysfunction-in-cancer-patients
#7
Kazuko Tajiri, Kazutaka Aonuma, Ikuo Sekine
Cardiac dysfunction that develops during or after completion of cancer therapy is a growing health concern that should be addressed in a multidisciplinary setting. Cardio-oncology is a new discipline that focuses on screening, monitoring and treating cardiovascular disease during and after cancer treatment. A baseline cardiovascular risk assessment is essential. For high-risk patients, a tailored and detailed plan for cardiovascular management throughout treatment and beyond should also be established. Anthracycline and/or trastuzumab-containing chemotherapy and chest-directed radiation therapy are well known cardiotoxic cancer therapies...
May 15, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28485067/chemotherapy-related-cardiotoxicity-are-australian-practitioners-missing-the-point
#8
Rachel Conyers, Ben Costello, Anne Tripaydonis, Charlotte Burns, Louise Ludlow, Peter Lange, Paul Ekert, Francoise Mechinaud, Michael Cheung, Michelle Martin, David Elliot
BACKGROUND: It has long been established that cardiotoxicity occurs as a result of exposure to certain chemotherapeutics, particularly anthracyclines. Historically, clinicians equate cardiotoxicity with a poor prognosis, in a small percentage of patients and deem long-term surveillance as optional. Emerging evidence suggests that anthracycline cardiotoxicity (ACT) is a life-long risk with an incidence approaching 20%. METHODS: Participants were identified via the Haematology-Oncology (HO) database at the Royal Children's Hospital, Melbourne...
May 9, 2017: Internal Medicine Journal
https://www.readbyqxmd.com/read/28474324/role-of-imaging-in-cardio-oncology
#9
REVIEW
Erick Avelar, Caitlin R Strickland, Guido Rosito
Recent advances in cancer treatment and research have greatly improved survival rates for patients with cancer. However, many of these cancer survivors are developing cardiac disease-most commonly heart failure as a result of this treatment. Certain chemotherapeutic agents, including anthracyclines and trastuzumab, have been linked to cardiotoxicity-induced cardiomyopathy in cancer patients. It has been reported as early as during infusion and as late as several years following treatment. Radiation therapy, particularly to the left breast, has also been linked to cardiac disease...
June 2017: Current Treatment Options in Cardiovascular Medicine
https://www.readbyqxmd.com/read/28353310/the-early-variation-of-left-ventricular-twisting-function-in-patients-with-lymphoma-received-anthracycline-therapy-assessed-by-three-dimensional-speckle-tracking-echocardiography
#10
Feiyan Song, Yu Kang, Chujie Zhang, Yuchen Xu, Jing Shi, Ye Guo, Qunling Zhang, Xianhong Shu, Leilei Cheng
BACKGROUND: Anthracycline-induced cardiotoxicity remains a significant and unresolved issue in patients receiving chemotherapy. The aim of this study was to evaluate left ventricular (LV) twisting function by three-dimensional speckle tracking echocardiography (3D-STE) in patients with lymphoma after anthracycline therapy. METHODS: One hundred and one patients with newly diagnosed diffuse large B-cell lymphoma who had planned to receive anthracycline chemotherapy were enrolled...
March 29, 2017: Cardiology Journal
https://www.readbyqxmd.com/read/28379383/2d-and-3d-strain-for-detection-of-subclinical-anthracycline-cardiotoxicity-in-breast-cancer-patients-a-balance-with-feasibility
#11
Ciro Santoro, Grazia Arpino, Roberta Esposito, Maria Lembo, Immacolata Paciolla, Cinzia Cardalesi, Giovanni de Simone, Bruno Trimarco, Sabino De Placido, Maurizio Galderisi
Aims: 2D echocardiography is limited for identifying chemotherapy-related cardiotoxicity. This study compared standard echo, 2D, and 3D speckle tracking echocardiography (STE) for detection of subclinical anthracycline (ANT) cardiotoxicity in breast cancer patients. Methods and results: One-hundred consecutive breast cancer patients free of cardiac symptoms were treated by multiple protocols including ANT and cyclophosphamide and/or 5-fluorouracil for 3-4 cycles...
March 31, 2017: European Heart Journal Cardiovascular Imaging
https://www.readbyqxmd.com/read/28275118/modern-management-of-anthracycline-induced-cardiotoxicity-in-lymphoma-patients-low-occurrence-of-cardiotoxicity-with-comprehensive-assessment-and-tailored-substitution-by-nonpegylated-liposomal-doxorubicin
#12
Jacopo Olivieri, Gian Piero Perna, Caterina Bocci, Claudia Montevecchi, Attilio Olivieri, Pietro Leoni, Guido Gini
BACKGROUND: Anthracyclines (AC) are still undeniable drugs in lymphoma treatment, despite occasionally causing cardiotoxicity. Liposomal AC may reduce cardiotoxicity while retaining clinical efficacy; also, biomarker monitoring during chemotherapy allows early detection of cardiac damage, enabling strategies to prevent left ventricular ejection fraction (LVEF) deterioration. MATERIALS AND METHODS: We conducted a prospective observational trial in a real-life population of lymphoma patients, combining advanced echocardiography and biomarkers (Troponin I [TnI]) for early detection of cardiotoxicity; we applied a prespecified policy to minimize cardiotoxicity, selecting patients with higher baseline risk to replace doxorubicin with nonpegylated liposomal doxorubicin (NPLD) and starting cardioprotective treatment when subclinical cardiotoxicity was detected...
April 2017: Oncologist
https://www.readbyqxmd.com/read/28279418/advanced-heart-failure-therapies-for-cancer-therapeutics-related-cardiac-dysfunction
#13
REVIEW
Christopher M Bianco, Sadeer G Al-Kindi, Guilherme H Oliveira
End-stage heart failure in cancer survivors may result from cardiotoxic chemotherapy and/or chest radiation and require advanced therapies, including left ventricular assist devices (LVADs) and transplantation. Traditionally, such therapies have been underutilized in cancer survivors owing to lack of experience and perceived risk of cancer recurrence. Recent data from large registries, however, have shown excellent outcomes of LVADs and transplantation in cancer survivors, albeit subject to careful selection and special considerations...
April 2017: Heart Failure Clinics
https://www.readbyqxmd.com/read/28283339/prinzmetal-angina-coronary-vasospasm-associated-with-5-fluorouracil-chemotherapy
#14
Maxim Ben-Yakov, Amal Mattu, William J Brady, Sarah B Dubbs
Several chemotherapeutic agents are known to be cardiotoxic. One of them, 5-fluorouracil (5-FU), has been associated with coronary ischemia and reversible vasospasm. In this report, we describe a 54-year-old man with rectal cancer who developed chest pain during 5-FU infusion. His initial electrocardiogram (ECG), obtained while he was experiencing chest pain, showed hyperacute T waves in the anterolateral leads. Those waves disappeared along with the chest pain after administration of sublingual nitroglycerine...
March 1, 2017: American Journal of Emergency Medicine
https://www.readbyqxmd.com/read/28265228/echocardiography-and-cardiac-biomarkers-in-patients-with-non-small-cell-lung-cancer-treated-with-platinum-based-chemotherapy
#15
Daniel Omersa, Tanja Cufer, Robert Marcun, Mitja Lainscak
BACKGROUND: Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains an important cause of cancer death worldwide. Platinum-based chemotherapy (PBC) for NSCLC can modify outcome while the risk of cardiotoxicity remains poorly researched. We aimed to evaluate the incidence and severity of cardiac injury during PBC in patients with NSCLC and to identify patients at risk. METHODS: This was a single-centre, prospective, observational study of patients with early and advanced stage NSCLC referred for PBC...
March 1, 2017: Radiology and Oncology
https://www.readbyqxmd.com/read/28254996/cardio-oncology-what-you-need-to-know-now-for-clinical-practice-and-echocardiography
#16
REVIEW
Carolyn M Larsen, Sharon L Mulvagh
Cardio-oncology is a rapidly growing field aimed at minimizing the effects of cardiovascular morbidity and mortality in cancer survivors. To meet this aim, patients are assessed at baseline to define their risk of cardiotoxicity and then followed closely during and after chemotherapy to assess for early signs or symptoms of cardiovascular disease. Cardiac imaging, and in particular, transthoracic echocardiography, plays an essential role in the baseline assessment and serial follow-up of cardio-oncology patients...
March 2017: Echo Research and Practice
https://www.readbyqxmd.com/read/28191909/the-influence-of-chemotherapy-on-the-right-ventricle-did-we-forget-something
#17
REVIEW
Marijana Tadic, Cesare Cuspidi, Dagmara Hering, Lucia Venneri, Oleksandr Danylenko
BACKGROUND: A large number of chemotherapy-induced cardiovascular complications were discovered in studies over the last several decades. The focus of the majority of these studies was left ventricular (LV) remodeling. The aim of this article was to provide a comprehensive overview of potential mechanisms of chemotherapy-induced right ventricular (RV) remodeling and summarize clinical studies on this topic. HYPOTHESIS: Chemotherapy induces RV structural, functional, and mechanical changes...
February 13, 2017: Clinical Cardiology
https://www.readbyqxmd.com/read/28185035/anthracycline-chemotherapy-and-cardiotoxicity
#18
REVIEW
John V McGowan, Robin Chung, Angshuman Maulik, Izabela Piotrowska, J Malcolm Walker, Derek M Yellon
Anthracycline chemotherapy maintains a prominent role in treating many forms of cancer. Cardiotoxic side effects limit their dosing and improved cancer outcomes expose the cancer survivor to increased cardiovascular morbidity and mortality. The basic mechanisms of cardiotoxicity may involve direct pathways for reactive oxygen species generation and topoisomerase 2 as well as other indirect pathways. Cardioprotective treatments are few and those that have been examined include renin angiotensin system blockade, beta blockers, or the iron chelator dexrazoxane...
February 2017: Cardiovascular Drugs and Therapy
https://www.readbyqxmd.com/read/28132957/risk-of-heart-failure-with-preserved-ejection-fraction-in-older-women-after-contemporary-radiotherapy-for-breast-cancer
#19
Hirofumi Saiki, Ivy A Petersen, Christopher G Scott, Kent R Bailey, Shannon M Dunlay, Randi R Finley, Kathryn J Ruddy, Elizabeth Yan, Margaret M Redfield
BACKGROUND: Cardiomyocytes are resistant to radiation. However, cardiac radiation exposure causes coronary microvascular endothelial inflammation, a perturbation implicated in the pathogenesis of heart failure (HF) and particularly HF with preserved ejection fraction (HFpEF). Radiotherapy for breast cancer results in variable cardiac radiation exposure and may increase the risk of HF. METHODS: We conducted a population-based case-control study of incident HF in 170 female residents of Olmsted County, Minnesota (59 cases and 111 controls), who underwent contemporary (1998-2013) radiotherapy for breast cancer with computed tomography-assisted radiotherapy planning...
April 11, 2017: Circulation
https://www.readbyqxmd.com/read/28122377/primary-prevention-strategies-for-anthracycline-cardiotoxicity-a-brief-overview
#20
Pierantonio Menna, Emanuela Salvatorelli
The clinical use of doxorubicin and other antitumor anthracyclines is limited by a dose-related risk of cardiomyopathy and heart failure which may occur "on treatment" or any time, from months to years, after completing chemotherapy. Dose reductions diminish the incidence of cardiac events attributable to anthracyclines, but heart failure still occurs in some patients exposed to low or moderate anthracycline doses. Because anthracyclines improve the life expectancy of patients with, for example, breast cancer or lymphomas, preventing or diminishing the risk of early or delayed cardiotoxicity is of obvious clinical importance...
2017: Chemotherapy
label_collection
label_collection
6870
1
2
2017-01-28 03:14:45
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"